Furthermore, study of 356 patients from Dana-Farber/Brigham and Women’s Cancer Center [24] and our results derived from the TCGA PAAD datasets showed that the KRAS, TP53 mutation and CDKN2A deletion were synergistically determined the clinical overall survival of patients with pancreatic cancer. Here, TP53 is linked to familial pancreatic carcinoma.